Ocular surface disease in patients with ocular hypertension and glaucoma

Current Eye Research

Volumn 36, Issue 5, 2011, Pages 391-398

  Stewart, William C ^a   Stewart, Jeanette A ^a   Nelson, Lindsay A ^b  

^a University of South Carolina   (United States)

^b Charleston Research Company LLC   (United States)

Author keywords

Glaucoma; Ocular surface disease; Preservative; Quality of life; Treatment

Indexed keywords

APRACLONIDINE; BENZALKONIUM CHLORIDE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; CARTEOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; FOTIL; LATANOPROST; PILOCARPINE; POLYQUATERNIUM 1; SAFLUTAN; SEVERAL; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

ANTERIOR EYE SEGMENT; BLEPHARITIS; DISEASE SEVERITY; DRY EYE; EYE ALLERGY; EYE DISEASE; EYE EXAMINATION; EYELID DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; OCULAR SURFACE DISEASE; OPEN ANGLE GLAUCOMA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; DRUG HYPERSENSITIVITY; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; PRESERVATIVES, PHARMACEUTICAL; PREVALENCE;

EID: 79955016801     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.562340     Document Type: Review

References (59)

1. Baudouin C, Labbé A, Liang H, et al. Preservatives in eye-drops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-334.
2. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496. (Pubitemid 38857008)
3. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
4. Stewart WC. Clinical Practice of Glaucoma. Thorofare, New Jersey: SLACK Inc., 1990.
5. Ritch R. The Glaucomas. St. Louis: Mosby-Year Book, Inc., 1996.
6. Stewart WC, Rhodes JS, Leech JN. Survey assesses red eye and prostaglandin use. Review Ophthalmol. Apr 2002;72-73.
7. Tsai JH, Derby E, Holland EJ, et al. Incidence and preva-lence of glaucoma in severe ocular surface disease. Cornea. 2006;25:530-532. (Pubitemid 44641588)
8. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572-579.
9. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618-621.
10. Erb C, Gast U, Schremmer D. German register for glau-coma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593-1601.
11. Schmier JK, Covert DW. Characteristics of respondents with glaucoma and dry eye in a national panel survey Clin Ophthalmol. 2009;3:645-650.
12. Perry HD. Dry eye disease: Pathophysiology, classifcation, and diagnosis. Am J Manag Care. 2008;14(3 Suppl):S79-S87 (Pubitemid 351656965)
13. Defnition,and Classifcation Subcommittee of the International Dry Eye WorkShop. The defnition and clas-sifcation of dry eye disease: Report of the Defnition and Classifcation Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75-92
14. American Academy of Ophthalmology, Preferred Practice Patterns. Cornea/External Disease Panel, Blepharitis. San Francisco, 2008.
15. Tong L, Chaurasia SS, Mehta JS, et al. Screening for mei-bomian gland disease: Its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010;51:3449-3451.
16. Asbell PA, Lemp MA. Dry eye disease. In: The Clinician's Guide to Diagnosis and Treatment. New York: Thieme, 2006.
17. Baudouin C Conditions bordering on allergy J Fr Ophtalmol. 2007;30:306-313.
18. Shah-Desai S, Sandy C, Collin R. Lax eyelid syndrome or 'progeria' of eyelid tissues. Orbit. 2004;23:3-12. (Pubitemid 38375706)
19. Geerling G, Borrelli M. Adnexal surgery for severe ocular surface disease. Semin Ophthalmol. 2005;20:101-112. (Pubitemid 40904297)
20. Henry JC, Peace JH, Stewart JA, et al. Effcacy, safety and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy Clin Ophthalmol. 2008;2:613-621.
21. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin prepara-tion in topical glaucoma medication. Acta Ophthalmol. 2010;88:329-336.
22. Baudouin C Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80-86. (Pubitemid 26268834)
23. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94. (Pubitemid 30099159)
24. Pisella PJ, Lala E, Parier V, et al. Effect of preservatives on the conjunctiva: A comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients. J Fr Ophtalmol. 2003;26:675-679. (Pubitemid 37169056)
25. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface infammatory changes induced by topical antiglau-coma drugs: Human and animal studies. Ophthalmology. 1999;106:556-563. (Pubitemid 30191592)
26. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses infammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109-115.
27. Levrat F, Pisella PJ, Baudouin C Clinical tolerance of anti-glaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe. J Fr Ophtalmol. 1999;22:186-191. (Pubitemid 29197605)
28. de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: Epithelial permeability and autofuorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221-224. (Pubitemid 24127409)
29. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-349. (Pubitemid 47056287)
30. Blondin C, Hamard P, Cholley B, et al. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res. 2003;27:253-259. (Pubitemid 37315485)
31. Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241:1037-1043. (Pubitemid 38028900)
32. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proin-fammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vitro study Invest Ophthalmol Vis Sci. 2004;45:1360-1368. (Pubitemid 38859312)
33. Chigbu DI. The management of allergic eye diseases in pri-mary eye care. Cont Lens Anterior Eye. 2009;32:260-272.
34. Pisella PJ. Pathology of the ocular surface. Rev Prat. 2006;56:1226-1231.
35. Calonge M, Herreras JM. Clinical grading of atopic kerato-conjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7:442-445.
36. Rao SK, Basti S, Lin A, et al. The itching, burning eye: Diagnostic algorithm and management options. Compr Ophthalmol Update. 2006;7:157-167. (Pubitemid 44453096)
37. Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol. 1986;31:145-158. (Pubitemid 17222026)
38. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987;27:27-35.
39. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118-122. (Pubitemid 40075430)
40. American Academy of Ophthalmology, Preferred Practice Patterns. Dry Eye Syndrome. San Francisco, 2008.
41. Kramer P, York KK, Lubkin V, et al. Comparative levels of sex steroid hormones in lacrimal and salivary secretions and blood. Invest Ophthalmol Vis Sci. 1983;24:55.
42. Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: The infuence of prolactin and sex hormones on human tear production. Cornea. 1998;17:353-358. (Pubitemid 28307498)
43. Pfugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-flm disorders known to cause ocular irrita-tion. Cornea. 1998;17:38-56. (Pubitemid 28047008)
44. Lamberts DW. Dry eye and tear defciency Int Ophthalmol Clin. 1983;23:123-130.
45. Norn M. The effects of drugs on tear fow. Trans Ophthalmol Soc UK. 1985;104:410-414.
46. Thoft RA. Relationship of the dry eye to primary ocular surface disease. Trans Ophthalmol Soc UK. 1985;104:452-457. (Pubitemid 15061307)
47. Labbé A, Baudouin C Treatment of glaucoma in patients with dry eye syndrome. J Fr Ophtalmol. 2010;33:285-290.
48. Anwaruddin R, Herrygers L, Noecker RJ. Effect of preser-vatives on the ocular surface in chronic glaucoma therapy Invest Ophthalmol Vis Sci. 2002;43:E-Abstract 4088.
49. Kahook MY, Noecker RJ. Comparison of corneal and con-junctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artifcial tears. Cornea. 2008;27:339-343. (Pubitemid 351440870)
50. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafuprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303-312. (Pubitemid 351507760)
51. Ammar DA, Noecker RJ, Kahook MY Effects of benzalko-nium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837-845.
52. Horsley MB, Kahook MY Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.
53. Mundorf T, Wilcox KA, Ousler GW 3rd, et al. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther. 2003;20:329-336. (Pubitemid 38332673)
54. Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the effcacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fxed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757-1764.
55. Godfrey DA, Peplinski LS, Stewart JA, et al. A comfort com-parison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:189-194.
56. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexam-ethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo- keratoconjunctivitis. Adv Ther. 2007;24:60-67. (Pubitemid 46700866)
57. Smith GT, Lee S, Taylor HR. Open evaluation of a new non-preserved artifcial tear. Aust N Z J Ophthalmol. 1993;21:105-109. (Pubitemid 23276158)
58. Detry-Morel M. Side effects of glaucoma medications. Bull Soc Belge Ophtalmol. 2006;299:27-40.
59. Chan K Testa M, McCluskey P. Ocular comfort of com-bination glaucoma therapies: Brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23:372-376. (Pubitemid 350195062)